Metastatic Melanoma Market Overview
Metastatic Melanoma Market size is estimated to reach $12.1 billion by 2027, growing at a CAGR of 7.3% during the forecast period 2022-2027. Metastatic melanoma happens when cancer spreads from the tumor to additional portions of the body. This is also termed stage 4 melanoma. Melanoma is the most probable of all skin cancers to become metastatic if not detected early. A typical Metastatic Melanoma Industry application involves the manufacture of medications like Ipilimumab, Imatinib and Vemurafinib for the treatment of metastatic melanoma. The method of sentinel lymph node biopsy is in use for nearly ten years. However, its impact on survival has not yet been entrenched. Mohs surgery is an advanced surgical method that accurately eliminates numerous forms of skin cancer while conserving healthy surrounding tissue. Mohs surgery may be utilized to treat melanoma on the face, scalp or ears that includes the top layer of the skin (epidermis) and is termed melanoma in situ (principally lentigo maligna type). The process can entirely eliminate the melanoma while sparing as much normal skin around the tumor as possible. If melanoma did not grow in a contiguous fashion prior to metastasis, the outcomes of Mohs surgery would be inferior to wide excision and greater local recurrences would be anticipated. Alternatively, the superior outcomes support the concept of contiguous tumor growth. In July 2022, it was reported that blood type may affect response to immune checkpoint inhibitors (ICI) therapy in patients with metastatic cancer, as per an investigation circulated in The Oncologist. Opdualag – a fixed-dose combination of LAG-3 inhibitor relatlimab and BMS’ PD-1 inhibitor Opdivo (nivolumab) – was certified as first-line therapy for unresectable or metastatic melanoma by the U.S. Food and Drug Administration (FDA) in March and garnered $58 million in sales in the second quarter. For patients with some kinds of melanoma, YERVOY is a certified treatment option. Imiquimod cream seems to be a feasible alternative for primary or adjuvant treatment of lentigo maligna (LM) in senior patients who are poor surgical candidates.
The surging technological progress, increasing focus on immune checkpoint inhibitors and enhanced sophistication in healthcare facilities globally are set to drive the Metastatic Melanoma Market. The increasing government initiatives connected to early diagnosis and treatment awareness are set to propel the growth of the Metastatic Melanoma Industry during the forecast period 2022-2027. This represents the Metastatic Melanoma Industry Outlook.
Metastatic Melanoma Market Report Coverage
The “Metastatic Melanoma Market Report - Forecast (2022-2027)” by Industry ARC, covers an in-depth analysis of the following segments in the Metastatic Melanoma Market.
- Geographically, North America (Metastatic Melanoma Market share) accounted for the highest revenue share in 2021 and it is poised to dominate the market over the period 2022-2027 owing to the increasing predominance of melanoma and additional skin cancers requiring the application of Mohs surgery in the North American region.
- Metastatic Melanoma Market growth is being driven by approved diagnostics and therapeutics and medications like Opdualag together with positive prospects succeeding the continuing research findings to treat the ailment and boost the lifespan of patients. However, metastatic melanoma is more challenging to treat and this is one of the major factors hampering the growth of the Metastatic Melanoma Market.
- Metastatic Melanoma Market Detailed Analysis of the Strengths, Weaknesses and Opportunities of the prominent players operating in the market would be provided in the Metastatic Melanoma Market report.
Metastatic Melanoma Market Segment Analysis - by Treatment Option
The Metastatic Melanoma Market based on treatment options can be further segmented into Surgery, Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy and Clinical Trials. The Immunotherapy Segment held the largest Metastatic Melanoma Market share in 2021. This growth is owing to the surging efficiency of medications utilized in immunotherapy and a boost in their approvals. Sentinel Lymph Node Biopsy (SLNB) is a specially designed procedure performed to conclude whether any melanoma cells have spread to the sentinel nodes. The soaring attention on immune checkpoint inhibitors for the treatment of Metastatic Melanoma is further propelling the growth of the Immunotherapy segment.
Furthermore, the Targeted Therapy segment is estimated to grow with the fastest estimated CAGR of 9.1% during the forecast period 2022-2027 owing to the growing application of targeted therapy attributed to advantages like restricted negative impacts and greater efficiency of targeted therapy medications.
Metastatic Melanoma Market Segment Analysis - by End-use Industry
The Metastatic Melanoma Market based on the end-use industry can be further segmented into Hospitals, Specialty Clinics, Home Healthcare, Medical Research Organizations and Others. The Hospitals Segment held the largest Metastatic Melanoma Market share in 2021. This growth is owing to the increasing inclination of patients toward hospitals for diagnosis of Metastatic Melanoma. Mohs surgery is a progressive surgical method that accurately eliminates numerous forms of skin cancer while conserving healthy surrounding tissue. The presence of advanced infrastructure and the effortless availability of qualified and skilled physicians and multidisciplinary teams in hospitals is further propelling the growth of this segment.
Furthermore, the Specialty Clinics segment is estimated to grow with the fastest CAGR of 8.3% during the forecast period 2022-2027. This is because of the surging count of specialty clinics including Metastatic Melanoma Clinics and Melanoma Clinics in developed countries like the U.S. utilizing medications like Opdivo, Yervoy and imiquimod cream for the treatment of melanoma.
Metastatic Melanoma Market Segment Analysis - by Geography
The Metastatic Melanoma Market based on geography can be further segmented into North America, Europe, Asia-Pacific, South America and the Rest of the World. North America (Metastatic Melanoma Market) held the largest Metastatic Melanoma Market share with 37% of the overall market in 2021. The growth of this region is owing to the increasing count of people being diagnosed with skin cancer on a day-to-day basis in the U.S. The existence of key players like Abbott in the U.S. and the increasing application of medications like Yervoy and imiquimod cream for the treatment of different kinds of skin cancer including Metastatic Melanoma is further propelling the growth of the Metastatic Melanoma Industry, thereby contributing to the Metastatic Melanoma Industry Outlook in the North American region.
Furthermore, the Asia-Pacific region is estimated to be the region with the fastest CAGR rate over the forecast period 2022-2027. This growth is owing to factors like the increasing predominance of skin cancer together with the heightened demand for cost-efficient therapeutics in the Asia-Pacific region. The existence of an enormous count of clinical research organizations and the rising application of Opdivo for the treatment of Melanoma is further fuelling the progress of the Metastatic Melanoma Market in the Asia-Pacific region.
Metastatic Melanoma Market Drivers
Surging Applications of Immune Checkpoint Inhibitors are Projected to Drive the Growth of Metastatic Melanoma Industry:
As per Metastatic Melanoma Statistics on healthresearchfunding.org, Metastatic melanoma is responsible for 4.6% of all novel cancer cases that are diagnosed. Sentinel lymph node biopsy (SLNB) is an extensively accepted process for melanoma staging and treatment. Mohs surgery is performed by a specially trained dermatologist or surgeon. In this process, the skin (involving melanoma) is eliminated in very thin layers. Programmed cell death 1 (PD-1) inhibitors are members of a novel class of medications termed immune checkpoint inhibitors and have proven efficiency in the treatment of metastatic melanoma. The application of nivolumab and pembrolizumab has been recorded in patients with metastatic conjunctival melanoma and with metastatic cutaneous melanoma and orbital involvement. The response of the metastatic ailment of patients was good the medications. Certain patients have finished therapy and stay ailment free at least 1 year subsequent to finishing treatment. One patient is still accepting treatment and his orbital ailment is responding. The surging applications of immune checkpoint inhibitors are therefore fuelling the growth of the Metastatic Melanoma Industry, thereby contributing to the Metastatic Melanoma Industry Outlook, during the forecast period 2022-2027.
Soaring Approvals of Medications for Metastatic Melanoma are Expected to Boost the Growth of the Metastatic Melanoma Market:
As per Metastatic Melanoma Statistics on healthresearchfunding.org, novel cases of melanoma have been increasing by 1.8% per year for the last ten years. Sentinel lymph node biopsy (SLNB) has evolved into a well-established examination for evaluating microscopic nodal metastasis in melanoma. On March 18, 2022, the U.S. Food and Drug Administration (FDA) certified nivolumab and relatlimab-rmbw (Opdualag, Bristol-Myers Squibb Company) for adult and pediatric patients 12 years of age or older with unresectable or metastatic melanoma. “Opdualag is a fixed-dose combination of the LAG-3-blocking antibody relatlimab and the programmed death receptor-1 blocking antibody nivolumab”. Efficiency was assessed in RELATIVITY-047 (NCT03470922), a randomized (1:1), double-blinded trial in 714 patients with formerly untreated metastatic or unresectable Stage III or IV melanoma. The trial did not include patients with active autoimmune disease, medical conditions needing systemic treatment with moderate or high dose corticosteroids or immunosuppressive medicines, uveal melanoma and active or untreated brain or leptomeningeal metastases. Patients were randomized to accept Opdualag (nivolumab 480 mg and relatlimab 160 mg) by intravenous infusion every 4 weeks or nivolumab 480 mg by intravenous infusion every 4 weeks until disease progression or unacceptable toxicity. The principal efficiency outcome measure was progression-free survival (PFS) decided by Blinded Independent Central Review (BICR) utilizing RECIST v1.1. The trial showed a statistically significant enhancement in PFS by BICR for Opdualag in comparison with nivolumab (HR=0.75; 95% confidence interval [CI]: 0.62, 0.92; p-value=0.0055). The soaring approvals of medications for Metastatic Melanoma are therefore driving the growth of the Metastatic Melanoma Market during the forecast period 2022-2027.
Metastatic Melanoma Market Challenge:
Reoccurrence of Metastatic Melanoma is Hampering the Growth of the Metastatic Melanoma Market:
As per Metastatic Melanoma Statistics on healthresearchfunding.org, the percentage of cancer demises each year that are attributed to metastatic melanoma is 1.7%. Symptoms of Metastatic Melanoma include hardened lumps under the skin, bloated or painful lymph nodes, hardship in breathing or a cough that does not leave if cancer has spread to the lungs. Metastatic melanoma can recur and can even return in additional portions of the body. Early detection is vital to treating melanoma successfully prior to it becoming metastatic. Spindle cell melanoma occasionally displays the diagnostic cytologic features and immunoreactivity of conventional melanoma. Changing degrees of cytologic atypia and likely cell type differences from the primary counterpart or metastatic melanoma happening elsewhere are added sources of diagnostic challenges, specifically in the metastatic setting. Familiarity with cytologic features, integrated with clinical and immunoperoxidase findings, is needed to prevent misunderstanding. These issues are thus hampering the growth of the Metastatic Melanoma Market.
Metastatic Melanoma Industry Outlook
Novel product development, regional expansions, partnerships, development and approval of novel biologics, regional expansions and R&D activities are key strategies adopted by players in the Metastatic Melanoma Market. The top 10 companies in the Metastatic Melanoma market are:
- Abbott Diagnostics
- F. Hoffmann-La Roche AG
- GlaxoSmithKline Plc.
- Agilent Technologies
- Novartis AG
- Merck & Co. Inc.
- Sanofi S.A.
- Pfizer Inc.
- Bristol-Myer Squibb
- AstraZeneca Plc.
- In October 2021, AstraZeneca India Private Limited, the Global Capability Centre (GCC) of AstraZeneca, introduced a clinical data and insights division in India to further enhance its presence worldwide and for the handling of data-related facets of its clinical trials. The Clinical Data & Insights team in Bengaluru, India, is a crucial improvement to back a burgeoning global portfolio and work on internal data expertise.
- In May 2021, it was indicated that POSEIDON was a Phase III trial of AstraZeneca’s Imfinzi (durvalumab) plus platinum-based chemotherapy or Imfinzi, tremelimumab and chemotherapy versus chemotherapy alone in the 1st-line treatment of patients with Stage IV (metastatic) non-small cell lung cancer (NSCLC).
- In February 2020, AstraZeneca India introduced Qtern®, a progressive and convenient treatment alternative for type 2 diabetes patients. Qtern® is indicated as an adjunct to diet and exercise to enhance glycaemic control in mature grown-ups with type 2 diabetes mellitus (T2DM).
Report Code: HCR 0340
Report Code: HCR 1491
Report Code: HCR 66298
For more Lifesciences and Healthcare Market reports, please click here